Worldwide, millions of people are exposed to arsenic in drinking water that exceeds the World Health Organization standard of 10 g/liter by as much as 50 -300-fold, yet little is known about the molecular basis for arsenic excretion. Here we show that transport of arsenic into bile depends on the MRP2/cMOAT transporter and that glutathione is obligatory for such transport. Using reversed phase liquid chromatography/mass spectrometry, we demonstrate that two arsenic-glutathione complexes not previously identified in vivo, arsenic triglutathione and methylarsenic diglutathione, account for most of the arsenic in the bile. The structure of the compounds was also confirmed by nuclear magnetic resonance spectroscopy. Our findings may help explain the increased susceptibility of malnourished human populations to arsenic.
Arsenic toxicity is a major public health problem. In Latin America, South Asia, Taiwan, and Japan, arsenic levels in drinking water have been reported as high as 1.5-3.4 mg/liter (1) (2) (3) (4) (5) . People exposed to these high levels of arsenic are prone to develop skin, bladder, and lung cancer and occlusive vascular disease ("blackfoot disease") (4, 6, 7) , and malnourished populations are at higher risk for these conditions (8, 9) . Although arsenic can be rapidly cleared from the body, the factors that control its transport into bile and feces are largely unknown. Previous studies of the clearance of inorganic arsenic have demonstrated the presence of arsenite, arsenate, monomethyl arsonic acid (MMA), 1 and dimethyl arsenic acid (DMA) in feces and urine (10, 11) , but these studies have not illuminated the molecular basis for transport or the nature of the transported products. GSH has been suggested to be important as an intracellular reductant for arsenic methylation and in arsenic transport (12) (13) (14) (15) . Multidrug resistanceassociated protein 2 (MRP2/cMOAT) is highly expressed in the bile canaliculus of hepatocytes and mediates hepatobiliary transport of many organic compounds including GSH (16 -19) . Based on these observations, we hypothesized that the transport of arsenic and its methylated derivatives might depend on the formation of arsenic-GSH complexes and their transport by MRP2/ cMOAT. This idea is supported by recent work in cultured cells and lower eukaryotes (Caenorhabditis elegans) that demonstrates arsenic transport by multidrug resistance-associated proteins (20) .
EXPERIMENTAL PROCEDURES
Animal Model-Rats (Rattus norvegicus) (Wistar; Harlan, Houston, TX) or TR Ϫ rats (on a Wistar background originally obtained from Dr. Oude Elferink of the Academic Medical Center, Department of Gastrointestinal and Liver Diseases, Amsterdam, The Netherlands) (6 -8 weeks of age) were anesthetized (Ketamine/Acepromazine/xylazine 25: 1:1, 1 ml/kg), and the common bile duct was cannulated with a 22-gauge needle attached to polyethylene tubing (PE-10), the distal end of which flowed into an Eppendorf tube resting on a small pad of dry ice. Sodium arsenite (Fisher), MMA (Supelco, Bellefonte, PA), and DMA (Aldrich) solutions in deionized distilled water were administered intravenously via the tail vein or orally at the doses indicated in the text. Buthionine sulfoximine (BSO) (10 mmol/kg) (Sigma) was administered intraperitoneally 4 h prior to bile duct cannulation, and rats were maintained on water containing 20 mM BSO until anesthetized. All procedures followed guidelines established by the United States Public Health Service Policy on Humane Care and Use of Laboratory Animals and the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Baylor College of Medicine Animal Care and Use Committee.
Synthesis of Arsenic Triglutathione, Methylarsenic Diglutathione, and Dimethylarsenic Glutathione-The synthesis of ATG, MADG, and DMAG was carried out according to previously published procedures (21, 22) . Stoichiometric amounts of GSH and the respective arsenic species were mixed, and the reaction was carried out for 12 h under nitrogen atmosphere at room temperature. The experimental conditions for each of the arsenic-GSH complexes are as follows: ATG was prepared by dissolving sodium arsenite (0.129 g; 1 mmol) and GSH (0.921 g; 3 mmol) in 10 ml of degassed ultrapure water. At the end of the reaction, the ATG complex was precipitated with 40 ml of methanol, and the precipitate was filtered on a cellulose acetate membrane. Residual water was removed under reduced pressure without heating. Similarly, MADG was prepared by dissolving MMA (0.056 g, 0.4 mmol) and GSH (0.491 g, 1.6 mmol) in 2 ml of degassed ultrapure water and precipitating the product with ethanol. For DMAG preparation, DMA (0.138 g; 1 mmol) and GSH (0.921 g; 3 mmol) were dissolved in 10 ml of degassed ultrapure water, and at the end of the reaction the mixture was evaporated to dryness under reduced pressure without heating. The resulting powder was extracted with cold methanol (20 ml ϫ 4), and the extracts were combined and evaporated to dryness. The resulting powder was recrystallized from methanol/water (1:1), filtered, and dried.
Analysis of Arsenic by Inductively Coupled Argon Mass Spectrometry (ICP-MS)-Bile samples from arsenic-treated rats were diluted with 1% nitric acid and were analyzed for arsenic content by ICP-MS (HP 4500). Arsenic content in the bile was quantified using a standard calibration curve of inorganic arsenic (SPEX, Metchen, NJ) with terbium as an internal standard. The detection limits of ICP-MS for arsenic ranged between 100 and 200 parts per trillion. Arsenic levels in bile samples were expressed as g/ml bile.
Analysis of Arsenic-GSH Complexes and Arsenic by LC/ESI-MS and LC/ICP-MS-Mixtures
of synthetic ATG, MADG, and DMAG were separated on reversed phase HPLC column (Aqua C18 75 ϫ 2-mm column with a particle size of 3 m; Phenomenex, Torrance, CA) using 0.1% formic acid (pH 2.65) and an acetonitrile gradient (0 -40%). The column effluent was analyzed by monitoring negative ions by ESI-MS (HP1100). Mass spectra of ATG run under SCAN mode revealed several major fragmented ions including molecular ion (m/z 992), whereas MADG and DMAG showed specific mass fragmentation with their corresponding molecular ions, m/z 701 and m/z 410, respectively (please see the legend for Fig. 2 for details on the fragmentation). Selected ion monitoring was used to quantify the arsenic-GSH complexes in bile samples. The concentrations of these complexes were calculated on the basis of external standard calibration curves generated using synthetic ATG, MADG, and DMAG. In addition, the relative concentrations of arsenic in these complexes were analyzed by fractionating (20 s fractions) the bile sample on an LC column and analyzing the arsenic content by ICP-MS to compare the arsenic levels in these complexes with total arsenic in the bile. The data are presented as either total arsenic or arsenic present in these arsenic-glutathione complexes (ATG and MADG) per ml of bile. We also spiked bile samples with synthetic complexes to investigate their stability in bile. During these studies we found that MADG and DMAG were stable in bile (pH 8.0) with halflives of ϳ40 min, whereas ATG was found to have a half-life of 20 min. For this reason, we have collected bile samples at 2-min intervals (i.e. 18-20 min after intravenous administration of arsenic), and the bile samples were immediately used for the analysis of arsenic-GSH complexes by LC-MS. To determine the arsenic content in these complexes, a portion of this bile sample was fractionated using LC (20-s intervals), and the fractions were analyzed for total arsenic by ICP-MS.
Analysis of Arsenic-GSH Complexes by NMR-
The structures of arsenic-GSH complexes were further characterized by using a Bruker Avance 500 MHz spectrometer according to previously published methods (21, 22) . 1 H NMR data on GSH and its complexes with arsenic were collected at 25°C with a sweep width of 6068 Hz and a preacquisition delay of 5 s. 1 Hz broadening was applied before Fourier transformation. Arsenic-GSH complexes were prepared as described above except that GSH and mixtures of GSH and arsenic compounds (sodium arsenite, MMA, and DMA) were prepared in D 2 O for NMR experiments. The proton shifts in GSH and its complexes with arsenic are reported with the internal reference standard 3-(trimethylsilyl) 2,2,3,3, tetra deutero propionic acid sodium salt set to 0.0 ppm.
RESULTS
To develop a better understanding of arsenic excretion in bile, we administered sodium arsenite intravenously (0.5 mg/ kg) to Wistar rats and collected bile by cannulating the common bile duct. Using ICP-MS, we found that ϳ40% of administered arsenic was excreted into the bile and that the majority of this excretion took place during the first hour (Fig. 1) . Circumstantial evidence has suggested that GSH might be involved in arsenic transport (14, 15) . Because the MRP2/cMOAT transporter is known to transport organic anions including GSH (18, 19) , we reasoned that if GSH transport is an obligatory for arsenic excretion, TR Ϫ rats, known to be deficient in this transporter (16, 17) , should have reduced biliary excretion of arsenic. When we examined the biliary excretion of arsenic in these mutant rats, we found that they excreted Ͻ1% as much arsenic as wild-type Wistar rats (Fig. 1) . The biliary concentration of GSH was also reduced drastically in TR Ϫ rats to Ͻ1% of wildtype levels (18) . To rule out the possibility that the transport of GSH and the transport of arsenic are two separate processes Arsenic-glutathione complexes were synthesized according to the previously published procedures (21, 22) . ATG-MADG mixtures were separated on reversed phase HPLC column (Aqua C18 75 ϫ 2-mm column with a particle size of 3 m) (Phenomenex) using 0.1% formic acid (pH 2.65) and an acetonitrile gradient (0 -40%). The column effluent was analyzed by ESI-MS (HP1100) for negative ions. that both depend on MRP2/cMOAT pump, we used BSO, an inhibitor of GSH synthesis (23) , to examine the excretion of arsenic in Wistar rats in which the MRP2/cMOAT pump is intact. Pretreatment of Wistar rats with BSO (10 mmol/kg) reduced the biliary excretion of arsenic to Ͻ1% of control values (Fig. 1) , and the level of GSH excreted to 10% of control values (not shown). These data provide additional evidence for the essential role of GSH transport in the biliary excretion of arsenic.
We also examined the transport of MMA and DMA into bile by administering these compounds (0.5 mg/kg) intravenously to Wistar and TR Ϫ rats. Neither Wistar nor TR Ϫ rats excreted significant amounts of either MMA or DMA into bile (Ͻ1% as much arsenic as Wistar rats treated with sodium arsenite). These data suggest that for MMA or DMA to be excreted into bile, they must be formed in vivo within the liver, presumably by a mechanism involving GSH.
The implication of GSH in arsenic excretion prompted us to look for arsenic-GSH complexes as intermediates in arsenic transport. Although such complexes have not been identified in vivo to date, their existence has been postulated (21, 22, 24, 25) . We reasoned that failure to detect these complexes in the past might have resulted from their inherent instability and/or the choice of methods to extract and analyze body fluids. We synthesized three possible arsenic-GSH complexes, ATG, MADG, and DMAG ( Fig. 2A) , and developed methods for their separation and identification by LC/ESI-MS. Using these synthetic ATG, MADG, and DMAG standards, we found that the retention times for ATG, MADG, and DMAG were 3.8, 4.1, and 4.5 min, respectively (Fig. 2B) . These complexes were found to have specific mass fragmentation including their molecular ions (ATG, m/z 992; MADG, m/z 701; DMAG, m/z 410) (Fig. 2C) .
We used NMR to provide additional confirmation for the complex formation between GSH and arsenic compounds (sodium arsenite, MMA, and DMA). The chemical shifts of the cysteine residue ␤ protons of glutathione have been shown to be markers of complex formation with arsenic by NMR (21) . These ␤ protons shift downfield by 0.3-0.4 ppm upon forming the ATG complex ( Fig. 3 and Table I ). In the complex formed between MMA and glutathione (MADG), the ␤ protons shift downfield 0.2-0.3 ppm, whereas DMAG (a complex of DMA and GSH) displayed a downfield shift in these protons of about 0.2 ppm (Table I ). In addition to the ␤ proton shifts, the methyl protons of MMA shifted downfield 0.17 ppm upon formation of MADG, whereas the methyl protons of the DMA shift upfield about 0.6 ppm upon complex formation with GSH (Table I) . Minor changes in ␣ϪCH protons were also observed in these arsenic-GSH complexes (Table I) . These findings are in close agreement with those of Scott and collaborators (21) and Cullen and co-workers (22) and confirm the structures of these compounds.
To determine whether ATG, MADG, and DMAG ( Fig. 2A ) exist in vivo and are responsible for arsenic excretion, we intravenously injected Wistar rats with sodium arsenite (5 mg/kg) and analyzed the bile for the presence of these complexes by LC/ESI-MS. ATG and MADG were identified in bile samples of rats treated with arsenic (Fig. 4A ). We were unable to detect significant amounts of DMAG in bile samples. The   FIG. 3 . NMR analysis of synthetic arsenic-GSH complexes. Mixtures of glutathione and arsenic were prepared in D 2 O as described under "Experimental Procedures" and were analyzed using a 500 MHz Bruker Avance NMR spectrometer.
1 H NMR data on GSH and its complexes with arsenic were collected at 25°C with a sweep width of 6068 Hz and a preacquisition delay of 5 s. A, glutathione. B, ATG. C, MADG. The chemical shifts of the ␣ and ␤ protons of the glutamate, cysteine, and glycine moieties of GSH with reference to the internal reference standard 3-(trimethylsilyl) 2,2,3,3, tetra deutero propionic acid sodium salt set to 0.0 ppm are shown in A. The change in the chemical shifts in cysteinyl ␤ protons adjacent to the sulfydryl group (which directly participates in the complex formation between GSH and arsenic) for ATG and MADG are shown in B and C. The downfield change in chemical shifts of these ␤ protons is approximately 0.2-0.4 ppm. For more details on NMR analysis of these arsenic-glutathione complexes see Table I . total arsenic content in the bile was measured using ICP-MS (Table II) . To quantify the arsenic content in these complexes, we collected the LC column effluent of bile at 20-s intervals under the same chromatographic conditions and determined the arsenic content in these fractions using ICP-MS (Fig. 4B) . Most of the arsenic (80 -90%) eluted between 3.7 and 4.2 min (Fig. 4B) , indicating that arsenic-GSH complexes account for the majority of arsenic in the bile. Inorganic arsenic, MMA, and DMA elute in Ͻ1 min under these chromatographic conditions, and we found less than 10% of total arsenic in these fractions. At this dose, ATG and MADG were about equally abundant (Table II) . These data establish the role of arsenic-GSH complexes in arsenic excretion.
We extended our studies to examine the presence of these complexes in bile using lower doses of arsenic that are relevant to human exposure (1) (2) (3) (4) . For these experiments, Wistar rats were injected with either 0.5 or 0.1 mg/kg arsenic intravenously, and the bile was analyzed for ATG and MADG. We detected MADG and found that it accounted for 50 -60% of arsenic in bile at these doses (Table II) . ATG was undetectable at these doses. A likely explanation for this finding is that ATG is found only at high doses (5 mg/kg) because the ability of cells to methylate arsenic is saturated, whereas at lower doses all arsenic can be methylated.
The data on TR Ϫ rats (Fig. 1) suggest that virtually all arsenic in bile should be found associated with GSH. The reason we do not find 100% of arsenic associated with GSH is probably that dissociation of arsenic-GSH complexes occurs, especially at low doses of arsenic. The formation of ATG and MADG and their dissociation may be represented as follows (21) .
Because the forward reaction of each of the above equations depends on the exponential concentration of GSH (i.e.
[GSH] 3 for ATG formation and [GSH] 4 for MADG formation), the effect of changes in GSH concentration as a function of arsenic dose (Table II) is vastly magnified and drives the reaction toward the GSH arsenic complexes. The inability to detect ATG with low concentrations of arsenic exposure (0.1 and 0.5 mg/kg, intravenously) could also be partly because of the instability of this complex in bile (pH 8.0) (see "Experimental Procedures" for details).
Because human exposure is largely oral, we administered sodium arsenite to Wistar rats by gastric tube (5.0 mg/kg). We found that under these conditions the excretion of arsenic was slower; however, most of the arsenic was present as ATG and MADG (Table II) . At 0.5 mg/kg we were able to detect MADG but not ATG (data not shown) similar to our studies using intravenous administration of sodium arsenite (Table II) . DISCUSSION Our findings reveal several novel features of the biliary excretion of arsenic. We find that the hepatobiliary transport of arsenic depends on the bile canalicular MRP2/cMOAT transporter (Fig. 1) . It is well known that MRP2/cMOAT transports GSH and GSH conjugates (18, 19) ; our data demonstrate that arsenic is transported by this mechanism as well. Failure of TR Ϫ rats to excrete any (Ͻ1%) arsenic after loading with sodium arsenite suggests that both arsenic and one of its methylated products (MMA) are transported by this mechanism. This interpretation is supported by the findings of Gregus et al. (26) , which show that MMA is excreted into the bile of rats exposed to arsenite or arsenate. As expected from the results of others (18, 19) , transport of GSH in to bile was also diminished in TR Ϫ rats (Ͻ2% of controls rats). In addition, when wild-type Wistar rats were treated with BSO (an inhibitor of GSH synthesis) prior to arsenic administration, they also exhibit reduced arsenic levels in bile (Ͻ2% of control rats). These data indicate that both the MRP2/cMOAT transport system and GSH are essential for the biliary excretion of arsenic.
These observations prompted us to look for arsenic-GSH complexes in the bile. Although such complexes have not been identified in vivo to date, their existence has been postulated (21, 22, 24, 25) . We found two arsenic-GSH complexes not Table II . A portion of bile sample was also fractionated by LC and was used for the analysis of total arsenic by ICP-MS. Note that 80 -90% of arsenic was found in fractions between 200 and 300 s corresponding to the elution time of ATG and MADG (B).
previously identified in vivo, arsenic triglutathione and methylarsenic diglutathione. These account for most of the arsenic in the bile (Fig. 4 and Table II ). The inability of other investigators to identify these complexes probably results from the relative instability of these complexes. Our success may result from our avoidance of extraction prior to analysis and the use of LC-MS electrospray ionization. The increasing biliary GSH concentration with arsenic exposure is in close agreement with an earlier report (14) .
Our findings also raise the possibility that arsenic-GSH complex formation and transport by MRPs or multidrug-resistant proteins represent a general process by which cells clear arsenic. In this view, transport across the bile canalicular surface of the hepatocyte might represent a particularly efficient or well developed general mechanism. It is known, for example, that MRP2 is also expressed in kidney and lung, although at lower levels (16, 27) . Further, MRP2 is one of a family of multidrug-resistant proteins, some or all of which may be involved with arsenic transport (20, 28) . Also, our data provide a paradigm for the involvement of MRP1 and perhaps MRP2 in the renal excretion of arsenic (10, 28) .
Our present findings have significant implications for human health. We have used levels of arsenic that approximate those of people exposed to arsenic-contaminated water (1) (2) (3) (4) and of patients with acute promyelocytic leukemia receiving arsenic as chemotherapy (30, 31) . Arsenic is known to be more toxic in malnourished populations (8, 9) . In animals, proteinrestricted diets reduce liver GSH levels (32-34). We do not know precisely how much lowering of GSH is necessary to begin to reduce levels of excreted arsenic (Fig. 1) , but the observed increased toxicity of arsenic in humans on proteindeficient diets may result from less formation of arsenic GSHcomplexes and less excretion (2, 8, 9). With respect to leukemia patients receiving arsenic, studies of arsenic toxicity in cultured acute promyelocytic leukemia cells (NB4) and other malignant cell lines indicate that these cells have much lower intracellular GSH levels than nonmalignant cells and exhibit increased sensitivity to arsenic (29) . Treatment with N-acetyl cysteine, which preserves intracellular GSH levels, prevents arsenic-induced apoptosis in these cells. Our findings suggest that one reason why arsenic may be effective against promyelocytic leukemia is that increased toxicity results from reduced formation of arsenic-GSH complexes and subsequently less transport of arsenic out of these cells.
In summary, biliary transport of arsenic is dependent on formation of arsenic-GSH complexes and their transport out of hepatocytes by MRP2/cMOAT and into bile. Our findings provide a model for detoxification and clearance of arsenic at the cellular level.
TABLE II Analysis of total arsenic, ATG, and MADG in the bile of sodium arsenite-treated Wistar rats
Groups of four rats were intravenously treated with sodium arsenite, and bile collected between 18 and 20 min was analyzed for glutathionearsenic complexes using LC-MS and arsenic content in ATG and MADG by ICP-MS after fractionating the bile using reversed phase C-18 column (for more details see "Experimental Procedures"). Free GSH levels in bile were determined by LC-MS. Values are the means Ϯ S.E. ND, not detected. Values in parentheses are the percentages of total arsenic present as ATG or MADG. 
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